Skip to content
OpenCapital
Get started

Travere Therapeutics, Inc. TVTX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Viking Therapeutics logo
Viking TherapeuticsVKTX
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
——
Biogen logo
BiogenBIIB
——

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.2B+72.3%

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s available for sale securities debt securities current?
Travere Therapeutics, Inc. (TVTX) reported available for sale securities debt securities current of $130.59M in Q1 2026.
What is the long-term trend for Travere Therapeutics, Inc.'s available for sale securities debt securities current?
Over 4 years (2020 to 2025), Travere Therapeutics, Inc.'s available for sale securities debt securities current has grown at a -14.5% compound annual growth rate (CAGR), from $271.8M to $145.38M.